Latest studies
- Active not recruitingPHASE3
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study looks at a new drug, zanidatamab, combined with chemotherapy, and sometimes another drug called tislelizumab. It aims to see if this treatment works better and is safer than standard chemotherapy for advanced stomach and gullet cancers that have HER2.
Gastric NeoplasmsGastroesophageal AdenocarcinomaEsophageal AdenocarcinomaRomania - RecruitingPHASE3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This study looks at a new medicine, Maridebart cafraglutide, for people with heart failure and obesity. It aims to see if the medicine can reduce heart-related problems like hospital stays, improve symptoms, and help people live longer, alongside their usual heart failure care.
Heart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection FractionObesityRomania - RecruitingPHASE3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
This study looks at a new medicine, abelacimab, for people with an irregular heartbeat (atrial fibrillation) who can't take usual blood thinners. It compares abelacimab to a dummy medicine to see if it can prevent strokes.
Atrial Fibrillation (AF)Romania - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Empagliflozin Tablets 25 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Jardiance (Empagliflozin) 25 mg film-coated tablets, Marketing Authorisation Holder Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein Germany, in healthy adult, human subjects under fasting condition.
This study is comparing two different versions of a diabetes medicine called Empagliflozin. We want to see if a new version works the same as the original. Healthy adults will be given one dose and carefully checked.
DiabetesRomania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-2)
This study is testing a new medicine, dexpramipexole, for adults with severe asthma that affects their eosinophils (a type of white blood cell). We want to see if it reduces severe asthma attacks and improves breathing and quality of life over 52 weeks.
Severe Eosinophilic asthmaRomania - Active not recruitingPHASE3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study is looking at a new drug, quizartinib, combined with standard chemotherapy for adults recently diagnosed with a specific type of leukaemia called AML. We want to see if this combination improves treatment outcomes compared to chemotherapy alone.
LeukemiaRomania - RecruitingPHASE2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is testing a new medicine, Imeroprubart, for adults with a nerve condition called Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Researchers want to see if it's safe and helps improve symptoms compared to a dummy treatment.
Chronic Inflammatory Demyelinating PolyneuropathyRomania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease
This study is looking into a new treatment called Efgartigimod for Thyroid Eye Disease (TED). Researchers want to see how well it works, if it's safe, and if it causes any side effects. It's a big study involving many people, with some receiving the new drug and others a dummy treatment.
Thyroid Eye Disease (TED)Romania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
J2A-MC-GZGS: A Phase 3, Open-Label Study of Once Daily Orforglipron Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)
This study is testing a new medicine, Orforglipron, for adults with type 2 diabetes and who are overweight or obese. It's looking at how well it works compared to an insulin called Glargine to protect against heart problems.
Obesity, Chronic Kidney disease, Type 2 Diabetes, Cardiovascular Diseases, Overweight or Obesity, OverweightRomania - Active not recruitingPHASE3
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
This study looks at treating muscle-invasive bladder cancer. It compares standard chemotherapy with chemotherapy plus a new immunotherapy drug called nivolumab, given before and after surgery. The aim is to see if adding nivolumab helps more people.
Urinary Bladder NeoplasmsMuscle-Invasive Bladder CancerRomania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Eventdriven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis
This study is testing a new medicine, MK-2060, to see if it can stop blood clots forming in special tubes (grafts) used for kidney dialysis. We want to know if it's safe and if it works better than a dummy medicine (placebo) for people with serious kidney disease.
Prevention of arteriovenous graft thrombosisRomania - Active not recruitingPHASE3
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
This study looks at a new drug, Luspatercept, for people with myelofibrosis and anaemia who need regular blood transfusions and are already taking a JAK2 inhibitor. We want to see if it helps reduce the need for transfusions.
Myeloproliferative DisordersMyelofibrosisPrimary MyelofibrosisPost-Polycythemia Vera MyelofibrosisRomania - Active not recruitingPHASE3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
This study is testing a new medicine, ianalumab, for adults with active lupus nephritis. It compares ianalumab given every 4 or 12 weeks to a dummy medicine, alongside standard treatments, to see if it's safe and effective.
Lupus NephritisRomania - RecruitingPHASE3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
This study, called REMAP-CAP, looks at different treatments for serious lung infections like pneumonia, flu, and COVID-19 in adults needing intensive care. It aims to find out which treatments work best to help patients recover.
Community-acquired Pneumonia, Influenza, COVID-19Romania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis
This study is looking at a new medicine called Fipaxalparant for people with a serious skin condition called diffuse cutaneous systemic sclerosis. It's a second-stage trial to see how well it works and if it's safe over about a year.
Diffuse Cutaneous Systemic SclerosisRomania - RecruitingPHASE3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
This study is looking into a new medication called AZD0780. It aims to see if this medicine can lower the risk of serious heart problems like heart attacks or strokes in people who have already had them, or in those at high risk of having one for the first time.
Cardiovascular DiseaseRomania - AuthorisedHuman Pharmacology (Phase I)- First administration to humans
A Participant- and Investigator--Blinded, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants with Chronic Kidney Disease
This study is testing a new medicine, OJR520, for people with kidney disease and healthy volunteers. The main goals are to check if it's safe, how the body handles it, and if it has any effects. It’s a carefully designed study where some people get the medicine and others get a dummy treatment.
Chronic Kidney DiseaseRomania - RecruitingPHASE1, PHASE2
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
This study is testing a new medicine, CRB-701, for people with certain advanced solid cancers. It aims to find a safe and effective dose, and see which cancers it can treat. Participants will receive the medicine and have tests to check how it works.
Solid Tumor, AdultRomania - Active not recruitingPHASE3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
This study looks at a new way to treat a type of leukaemia (blood cancer) called B-cell precursor acute lymphoblastic leukaemia (ALL) in older adults. It compares a drug called Blinatumomab combined with gentler chemotherapy against the usual chemotherapy treatment to see which works best.
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Romania - RecruitingPHASE3
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
This study looks at a new treatment called Pumitamig for advanced non-small cell lung cancer that hasn't been treated before. It compares Pumitamig to an existing treatment, Pembrolizumab, in people whose cancer cells have a high level of a specific marker called PD-L1.
Non-Small Cell Lung Cancer (NSCLC)Romania - Active not recruitingPHASE3
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
This study is looking into a new combination of medicines for people in the UK with multiple myeloma that has come back or not responded to previous treatments. It compares a new medicine combination with a standard one to see if the new option works better.
Relapsed or Refractory Multiple MyelomaRomania - RecruitingPHASE3
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
This study is looking at a new drug, casdatifan, combined with an existing one, cabozantinib, for advanced clear cell kidney cancer. It compares this combination to cabozantinib with a dummy drug (placebo) to see if it stops cancer growth for longer in patients who've already had immunotherapy.
Metastatic Clear Cell Renal Cell CarcinomaAdvanced Clear Cell Renal Cell CarcinomaRomania - RecruitingPHASE2, PHASE3
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
This study is looking for children with achondroplasia, a type of dwarfism, who haven't had prior growth treatment. It compares a new medicine called BMN 333 with an existing one, Vosoritide, to see how well they help children grow and if they are safe.
AchondroplasiaRomania - RecruitingPHASE3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This study looks at a new combination of drugs, adagrasib, pembrolizumab, and chemotherapy, for people with a specific type of advanced non-small cell lung cancer (NSCLC) that hasn't been treated before and has a KRAS G12C gene change.
Carcinoma, Non-Small-Cell LungRomania - Active not recruitingPHASE3
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
This study, KRYSTAL-10, is for people with advanced bowel cancer that has a specific genetic change (KRAS G12C). It compares a combination of new drugs, MRTX849 and cetuximab, against standard chemotherapy to see which works better for those who have already had initial treatment.
Advanced Colorectal CancerMetastatic Colorectal CancerRomania - RecruitingNA
Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders
This study looks at whether using genetic information to guide medication choices can improve treatment for people with mood, anxiety, or psychotic disorders. It compares this personalised approach to standard care over 24 weeks.
Mood DisordersAnxiety DisordersPsychotic DisordersRomania - RecruitingPHASE3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
This study is looking at two different treatments, pumitamig and durvalumab, for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that can't be removed by surgery. It's for patients who have already had chemotherapy and radiation.
Non-small Cell Lung Cancer (NSCLC)Romania - RecruitingPHASE3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
This study compares new ways to treat advanced lung cancer. It looks at two drug combinations, Nivolumab and Relatlimab plus chemotherapy, versus Pembrolizumab plus chemotherapy. The goal is to find the best treatment for a specific type of lung cancer.
Non-small Cell Lung CancerRomania - RecruitingPHASE3
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This study compares two medicines, BGB-16673 and pirtobrutinib, for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when previous treatments haven't worked well enough. It aims to see which medicine is safer and more effective.
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaRomania - RecruitingPHASE3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
This study is looking at a new medicine called sacituzumab govitecan (SG) for people with a type of lung cancer called extensive stage small cell lung cancer (ES-SCLC) that has been treated before. We want to see if SG works better than standard treatments to help people live longer.
Extensive Stage Small Cell Lung Cancer (ES-SCLC)Romania - RecruitingPHASE3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
This study looks at new ways to treat advanced squamous non-small cell lung cancer. It combines standard treatment (Pembrolizumab, Carboplatin, Paclitaxel/Nab-paclitaxel) with a new drug, sac-TMT, to see if it helps people live longer.
Non-small Cell Lung CancerNSCLCRomania - Active not recruitingPHASE3
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
This study is testing a new medicine, tulisokibart, for people with moderate to severe ulcerative colitis. It aims to see if the medicine can help people feel better and stay in remission, compared to a dummy medicine, both in the short and long term.
Ulcerative ColitisRomania - Active not recruitingPHASE3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
This study is looking at a new medicine called frexalimab for people aged 18-55 with certain types of Multiple Sclerosis (MS). It compares frexalimab to an existing MS medicine, teriflunomide, to see how well it stops MS relapses and if it's safe.
Multiple SclerosisRomania - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
This study aims to see if adding the drug pembrolizumab to standard chemotherapy before and after surgery helps people with early-stage non-small cell lung cancer live longer and prevent the cancer from returning. It's a large study comparing this new approach with chemotherapy alone.
Non-small Cell Lung CancerRomania - Active not recruitingPHASE1
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
This study is for adults with head and neck cancer that has spread or returned. It tests if combining new medicines like BI 770371, pembrolizumab, and cetuximab can shrink tumors better than pembrolizumab alone. It aims to see if these combinations help the immune system fight cancer.
Head and Neck Squamous Cell CarcinomaRomania - Ongoing, recruitingTherapeutic exploratory (Phase II)
SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
This study is looking at a new medicine called SPI-62 for people with high cortisol levels caused by a non-cancerous lump on their adrenal gland. The main goal is to see if SPI-62 is safe and helps improve the condition.
Hypercortisolism related to benign adrenal tumourRomania - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
This study is looking into a new medication called remibrutinib for people with a type of multiple sclerosis (MS) called Secondary Progressive MS (SPMS). It will check if the medicine is safe and helps slow down the disease.
Secondary Progressive Multiple Sclerosis (SPMS)Romania - Active not recruitingPHASE3
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
This study looks at a new medicine called Seladelpar for Primary Biliary Cholangitis (PBC). It's a long-term study to see how safe and effective it is over time. Participants will have taken Seladelpar in a previous study.
Primary Biliary CirrhosisRomania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
H8H-MC-LAHW: A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine - PIONEER-PEDS2
This study, called PIONEER-PEDS2, is looking at a new medicine called Lasmiditan for children and teenagers with migraine headaches. It wants to see how safe the medicine is and if it causes any side effects over a year, specifically for each migraine attack treated.
MigraineRomania - RecruitingPHASE3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
This study looks at a new medicine, Baxdrostat, combined with an existing one, Dapagliflozin, for people with long-term kidney disease and high blood pressure. It aims to see if this combination can help protect the kidneys and heart better than Dapagliflozin alone.
Chronic Kidney Disease and HypertensionRomania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
This study is looking at a new medicine called INCB099280 for people with a type of skin cancer called advanced cutaneous squamous cell carcinoma. It's for patients whose cancer hasn't been treated with immunotherapy before and can't be cured by surgery or radiotherapy.
Treatment of immunotherapy-naive patients with previously untreated or recurrent locally advanced or metastatic cSCC not amenable to curative surgery and/or radiotherapyRomania - RecruitingPHASE3
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
This study is looking at two new drug combinations for adults newly diagnosed with Chronic Lymphocytic Leukemia (CLL). It compares sonrotoclax plus zanubrutinib with venetoclax plus acalabrutinib to see which is more effective and safer for treating this type of blood cancer.
Chronic Lymphocytic LeukemiaRomania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)
This study is looking at a new combination of two medicines, nivolumab and relatlimab, for adults with advanced liver cancer that has progressed despite previous treatments. It aims to see how well this new combination shrinks tumors and if it's safe.
Advanced Hepatocellular CarcinomaRomania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A pivotal, multicentre, randomised, open-label, parallel-group trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgestrel Vaginal Delivery System) during 9 cycles in comparison with Desogestrel tablets 0.075 mg.
This study compares a new vaginal ring delivery system for contraception with a commonly used birth control pill. It aims to see how well each prevents pregnancy and how safe and tolerable they are for women.
Prevention of pregnancyRomania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
This study is testing a drug called Olaparib for people with advanced cancer that has specific genetic changes (HRRm or HRD positive). Researchers want to see if the drug can shrink tumours, if it's safe, and how long people respond to it.
Treatment of participants with positive cancer for HRRm or HRD.Romania - RecruitingPHASE2
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
This study is testing a new medicine, Vamifeport, for people with a common type of iron overload called hereditary hemochromatosis. It aims to see if the medicine can reduce the amount of iron stored in the liver. Two groups will be compared: one getting the medicine and one getting a dummy pill.
Homeostatic Iron Regulator Gene-related Hereditary HemochromatosisRomania - Active not recruitingPHASE3
Avelumab Program Rollover Study
This study is for people with solid tumours already receiving a cancer medicine called avelumab in another clinical trial. It aims to safely continue their treatment and closely watch for any side effects, ensuring they receive ongoing care.
Solid TumorsRomania - RecruitingPHASE3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
This 52-week study is testing a new drug, depemokimab, for adults with uncontrolled Hypereosinophilic Syndrome (HES). It aims to see if depemokimab is effective and safe compared to a placebo, alongside their usual HES treatment.
Hypereosinophilic SyndromeRomania - AuthorisedHuman Pharmacology (Phase I)- First administration to humans
A First-in-Human, Open-label, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of NBIM-1008 in Patients with Rheumatoid Arthritis
This early-stage study is testing a new medicine called NBIM-1008 for people with rheumatoid arthritis. We want to see if it's safe, how the body handles it, and if it might help with symptoms. This is the first time it’s being given to humans.
Rheumatoid ArthritisRomania - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Naltrexone hydrochloride film-coated tablet, 50 mg, manufactured by Sun Pharmaceutical Industries Limited, India with NALTREXONE GH (naltrexone hydrochloride) film-coated tablets 50 mg, Product of Generic Health Pty Ltd Suite 2, Level 2 19-23 Prospect Street Box Hill, VIC, 3128, Australia, in healthy adult, human subjects under fasting condition.
This study is comparing two different versions of a medicine called naltrexone, which is used to help people with alcohol dependence. It's looking to see if both versions work the same way in healthy adults. This is a very early stage study, focusing on how the body handles the medicine.
Alcohol dependenceRomania